NASDAQ: ITRMIterum Therapeutics PLC Stock
$1.55-0.03 (-1.9%)
Updated Apr 24, 2024
ITRM Price
$1.55
Fair Value Price
-$1.04
Market Cap
$25.46M
52 Week Low
$0.62
52 Week High
$2.50
P/E
-0.52x
P/B
-3.98x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$38.37M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-5.1
Operating Cash Flow
-$39M
Beta
0.89
Next Earnings
May 10, 2024
Ex-Dividend
N/A
Next Dividend
N/A
ITRM Overview
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ITRM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ITRM ($1.55) is overvalued by 249.51% relative to our estimate of its Fair Value price of -$1.04 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ITRM ($1.55) is not significantly undervalued (249.51%) relative to our estimate of its Fair Value price of -$1.04 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ITRM is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ITRM due diligence checks available for Premium users.
Be the first to know about important ITRM news, forecast changes, insider trades & much more!
ITRM News
Valuation
ITRM fair value
Fair Value of ITRM stock based on Discounted Cash Flow (DCF)
Price
$1.55
Fair Value
-$1.04
Undervalued by
249.51%
ITRM ($1.55) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ITRM ($1.55) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ITRM is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ITRM price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.52x
Industry
15.69x
Market
41.27x
ITRM price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-3.98x
Industry
5.86x
ITRM's financial health
Profit margin
Revenue
$0.0
Net Income
-$12.4M
Profit Margin
0%
ITRM's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$26.3M
Liabilities
$32.7M
Debt to equity
-5.1
ITRM's short-term assets ($25.60M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ITRM's short-term assets ($25.60M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ITRM's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ITRM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$12.8M
Investing
$13.5M
Financing
$589.0k
ITRM's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ITRM vs Biotech Stocks
Iterum Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.